InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (9 ops.)
Insider track record
OtherDisclosed buys
0
Disclosed sells
9
T+90 hit rate
75%
T+90 mean return
+15.8%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Sandrock Alfred, Responsable de la Recherche et Développement. Director active across 2 companies, notably BIOGEN INC.. Cumulatively, 14 reports have been published. Split: 0 buy · 9 sells. Total volume traded: €5.9m. Activity tracked since 7 June 2021. The latest transaction was disclosed on 2 April 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations14 total
10,885 shares@ US$3.438.4% of flowCommon StockSEC:0001104659-25-032202:0
11,702 shares@ US$4.2411.7% of flowCommon StockSEC:0001104659-25-016520:0
16,644 shares@ US$4.4517.6% of flowCommon StockSEC:0001104659-25-012196:0
12,115 shares@ US$9.8627.2% of flowCommon StockSEC:0001104659-24-043104:0
13,033 shares@ US$7.4622.0% of flowCommon StockSEC:0001104659-24-026561:0
130,000 shares0Common StockSEC:0001104659-24-024982:0
7,437 shares@ US$7.8313.1% of flowCommon StockSEC:0001104659-23-042230:0
120,000 shares0Common StockSEC:0001104659-23-024418:0
100,000 shares0Common StockSEC:0001104659-22-037149:0
7,672 shares@ US$440.000.0097% mcap50.0% of flowCommon StockSEC:0001127602-21-019553:0
7,672 shares@ US$440.0050.0% of flowCommon StockSEC:0001127602-21-019553
1,278 sharesCommon StockSEC:0001127602-16-040394:0
426 sharesCommon StockSEC:0001127602-16-040394:1
852 sharesCommon StockSEC:0001127602-16-040394:2
14 of 14 declarations
About Sandrock Alfred
Alfred Sandrock is the Head of Research & Development and President & CEO of BIOGEN INC and Voyager Therapeutics, Inc. In these roles, he oversees research and development initiatives, aiming to innovate in the field of biological therapies. His scientific expertise is essential for the success of the companies' projects.
